Current Cardiology Reports

, Volume 5, Issue 3, pp 193–199

Sex differences in the causes and natural history of heart failure

  • Bobbi L. Hoppe
  • Denise D. Hermann
Article

Abstract

Heart failure is a clinical syndrome of increasing prevalence in the United States, with significant morbidity and mortality. Although men have a higher annual mortality rate, more women than men die from heart failure each year. Optimal disease management is critical in limiting the impact of heart failure on life quality, quantity, and health care expenditures. Women have a unique risk-factor profile and different clinical manifestations of heart failure than men. Understanding inherent sex differences in heart failure epidemiology, pathophysiology, and natural history is imperative in determining whether the optimal therapy for this prevalent and important syndrome is affected by sex.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: 2002 National Health Care Statistics. http://www.cdc.gov/nchs/data/hus/hus02.pdf. Accessed January 21, 2003.Google Scholar
  2. 2.
    American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.Google Scholar
  3. 3.
    Petrie MC, Dawson NF, Murdoch DR, et al.: Failure of women’s hearts. Circulation 1999, 99:2334–2341.PubMedGoogle Scholar
  4. 4.
    Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993, 22:6A-13A.PubMedCrossRefGoogle Scholar
  5. 5.
    Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham study. Circulation 2002, 106:3068–3072. Follow-up data from original Framingham study (1971–1996) useful in predicting the population burden of CHF.PubMedCrossRefGoogle Scholar
  6. 6.
    Redfield MM, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202.PubMedCrossRefGoogle Scholar
  7. 7.
    Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995, 26:1565–1574.PubMedCrossRefGoogle Scholar
  8. 8.
    Tandon S, Hankins SR, LeJemtel TH: Clinical profile of chronic heart failure in elderly women. Am J Geriatric Cardiol 2002, 11:318–323.Google Scholar
  9. 9.
    He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women. Arch Intern Med 2001, 161:996–1002.PubMedCrossRefGoogle Scholar
  10. 10.
    Kannel WB: Epidemiology aspects of heart failure. Cardiol Clin 1989, 7:1–9.PubMedGoogle Scholar
  11. 11.
    Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397–1402. Follow-up data from the Framingham study from years 1950 to 1999. Authors comment on the incidence and overall survival of patients with HF.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnstone D, Limacher M, Rousseau M, et al.: Clinical characteristics of patients in the Studies of Left Ventricular Dysfunction. Am J Cardiol 1992, 70:894–900.PubMedCrossRefGoogle Scholar
  13. 13.
    American Medical Association. Report 4 of the Council on Scientific Affairs. Presented at the 2000AMA Interim Meeting. Orlando, FL; December 3–6, 2000Google Scholar
  14. 14.
    Topol E, Traill T, Fortuin N: Hypertensive hypertrophy cardiomyopathy of the elderly. N Engl J Med 1985, 312:277–283.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoffman RM, Pstay BM, Kronal RA: Modifiable risk factors for the incident heart failure in the Coronary Artery Surgery Study. Arch Inter Med 1994, 154:417–423.CrossRefGoogle Scholar
  16. 16.
    Philbin EF, DiSalvo TG: Influence of race and gender on care process, resource use, and outcomes in congestive heart failure. Am J Cardiol 1998, 82:76–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Williams DG, Olsen EGJ: Prevalence of dilated cardiomyopathy in two regions in England. Br Heart J 1985, 54:153–155.PubMedGoogle Scholar
  18. 18.
    Codd MB, Sugrue DD, Gersh BJ, Melton J: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. Circulation 1989, 80:564–572.PubMedGoogle Scholar
  19. 19.
    Bagger JP, Bandruup U, Rasmussen K, et al.: Cardiomyopathy in western Denmark. Br Heart J 1984, 52:327–331.PubMedGoogle Scholar
  20. 20.
    Torp A: Incidence of congestive cardiomyopathy. Postgrad Med J 1978, 54:435–437.PubMedCrossRefGoogle Scholar
  21. 21.
    De Maria R, Gavazzi A, Recalcati F, et al., on behalf of the Italian Multicenter Cardiomyopathy Study Group: Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. Am J Cardiol 1993, 72:580–585.PubMedCrossRefGoogle Scholar
  22. 22.
    Haldeman GA, Rashidee A, Horswell R: Changes in mortality from heart failure-United States, 1980–1995. JAMA 1998, 280:874–875.CrossRefGoogle Scholar
  23. 23.
    Doughty R, Yee T, Sharpe N: Hospital admissions and deaths due to congestive heart failure in New Zealand. N Z Med J 1995, 108:474–475.Google Scholar
  24. 24.
    Reitsma JB, Mosterd A, De Craen AJM, et al.: Increase in hospital admission rates for heart failure in the Netherlands 1980–1993. Heart 1996, 76:388–392.PubMedGoogle Scholar
  25. 25.
    The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302.CrossRefGoogle Scholar
  26. 26.
    The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.CrossRefGoogle Scholar
  27. 27.
    Schocken DD, Arriata MI, Laever PE, Ross EA: Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992, 20:301–306.PubMedCrossRefGoogle Scholar
  28. 28.
    Mendes LA, Davidoff R, Cupples LA, et al.: Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997, 134:207–212.PubMedCrossRefGoogle Scholar
  29. 29.
    Carroll JD, Carroll EP, Feldman T, et al.: Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992, 86:1099–1107.PubMedGoogle Scholar
  30. 30.
    Crabbe DL, Dipla K, Ambati S, et al.: Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 2003, 41:300–306.PubMedCrossRefGoogle Scholar
  31. 31.
    Babiker FA, Windt LJ, van Eickels M, et al.: Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002, 53:709–719.PubMedCrossRefGoogle Scholar
  32. 32.
    Fischer M, Baessler A, Schunkert H: Renin-angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002, 53:672–677.PubMedCrossRefGoogle Scholar
  33. 33.
    Douglas PS, Katz SE, Weinberg EO: Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998, 32:1118–1125.PubMedCrossRefGoogle Scholar
  34. 34.
    Feldmer M, Kaling M, Takahashi S, et al.: Glucocorticoid and estrogen-responsive elements in the 5' flanking region of the rat angiotensinogen gene. J Hypertens 1991, 9:1005–1012.PubMedCrossRefGoogle Scholar
  35. 35.
    Clauser E, Gaillard I, Wei L, Corvol P: Regulation of angiotensinogen gene. Am J Hypertens 1989, 2:403–410.PubMedGoogle Scholar
  36. 36.
    Heiat A, Gross CP, Krumholz HM: Representation of the elderly, women and minorities in heart failure clinical trials. Arch Intern Med 2002, 162:1682–1688. Landmark study looking at a large collection of randomized controlled trials in HF. Authors comment on interesting epidemiologic trends.PubMedCrossRefGoogle Scholar
  37. 37.
    The CONSENSUS Trial Group: Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429–1435.CrossRefGoogle Scholar
  38. 38.
    Kimmelstiel C, Goldberg RJ: Congestive heart failure in women: focus on heart failure die to coronary artery disease and diabetes. Cardiology 1990, 77(Suppl 2):71–79.PubMedGoogle Scholar
  39. 39.
    The Trandolapril Cardiac Evaluation (TRACE) Group: A clinical trial of the angiotensin-converting enzyme trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670–1676.CrossRefGoogle Scholar
  40. 40.
    Ambrosioni E, Brghi C, Magnani B: The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995, 332:80–85.PubMedCrossRefGoogle Scholar
  41. 41.
    The SAVE Investigators: Effect of mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992, 327:669–677.CrossRefGoogle Scholar
  42. 42.
    Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450–1456.PubMedCrossRefGoogle Scholar
  43. 43.
    Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355.PubMedCrossRefGoogle Scholar
  44. 44.
    Ghali JK, Pina IL, Gottlieb SS, et al., on behalf of the MERIT-HF Study Group: Metoprolol CR/XL in female patients with heart failure. Analysis of the experiences in Metoprolol Extendedrelease Randomization Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002, 105:1585–1591.PubMedCrossRefGoogle Scholar
  45. 45.
    Packer M, Coats AJS, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.PubMedCrossRefGoogle Scholar
  46. 46.
    The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525–533.CrossRefGoogle Scholar
  47. 47.
    Rathore SS, Wang Y, Krumholz HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403–1411.PubMedCrossRefGoogle Scholar
  48. 48.
    American College of Cardiology/American Heart Association. Evolution and management of chronic heart failure in the adult: ACC/AHA practice guidelines for heart failure. J Am Coll Cardiol 2001, 37:340–370.CrossRefGoogle Scholar
  49. 49.
    Villareal RP, Woodruff AL, Massumi A: Gender and cardiac arrhythmias. Tex Heart Inst J 2001, 28:265–275.PubMedGoogle Scholar
  50. 50.
    Aronson D, Burger AJ: Gender related difference in modulation of heart rate in patients with congestive heart failure. J Cardiovasc Electrophysiol 2000, 11:1071–1077.PubMedCrossRefGoogle Scholar
  51. 51.
    Kudenchuck PJ, Bardy GH, Poole JE, et al.: Malignant ventricular tachyarrhythmias in women: Characteristics and outcome of treatment with an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 1997, 8:2–10.CrossRefGoogle Scholar
  52. 52.
    Pires LA, Sethuraman B, Guduguntla VD, et al.: Outcome of women versus men with ventricular tachyarrhythmias treated with the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2002, 13:563–568.PubMedCrossRefGoogle Scholar
  53. 53.
    Miller AP, Oparil S: Secondary prevention of coronary heart disease in women: A call to action. Ann Intern Med 2002, 138:150–151.Google Scholar
  54. 54.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 343:475–480.CrossRefGoogle Scholar
  55. 55.
    Manson JE, Greenland P, LaCroix AZ, et al.: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002, 347:716–725.PubMedCrossRefGoogle Scholar
  56. 56.
    Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in congestive heart failure. N Engl J Med 1986, 314:1547–1552.PubMedCrossRefGoogle Scholar
  57. 57.
    Cohn JN, Johnson G, ZIesche S, et al.: A comparison of enalapril with hydralazine-isorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedCrossRefGoogle Scholar
  58. 58.
    Pitt B, Martinez FA, Meurers GG: Randomized trial of losartan vs. captopril in patients with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997, 349:747–752.PubMedCrossRefGoogle Scholar
  59. 59.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Bobbi L. Hoppe
    • 1
  • Denise D. Hermann
    • 1
  1. 1.Division of Cardiology, UCSD Heart Failure and Cardiac Transplantation ProgramUniversity of California at San Diego Medical CenterSan DiegoUSA

Personalised recommendations